[go: up one dir, main page]

EP1789380A1 - Derives d'aminoadamantane, leurs procedes de production et leur utilisation - Google Patents

Derives d'aminoadamantane, leurs procedes de production et leur utilisation

Info

Publication number
EP1789380A1
EP1789380A1 EP05771230A EP05771230A EP1789380A1 EP 1789380 A1 EP1789380 A1 EP 1789380A1 EP 05771230 A EP05771230 A EP 05771230A EP 05771230 A EP05771230 A EP 05771230A EP 1789380 A1 EP1789380 A1 EP 1789380A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
groups
carbon atoms
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05771230A
Other languages
German (de)
English (en)
Inventor
Peter R. Schreiner
Lukas Wanka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Justus Liebig Universitaet Giessen
Original Assignee
Justus Liebig Universitaet Giessen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004035978A external-priority patent/DE102004035978A1/de
Application filed by Justus Liebig Universitaet Giessen filed Critical Justus Liebig Universitaet Giessen
Publication of EP1789380A1 publication Critical patent/EP1789380A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/14—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Definitions

  • the present invention relates to novel aminoadamantane derivatives and synthesis processes for the preparation of aminoadamantane derivatives.
  • the novel synthesis processes according to the invention make it possible for the first time to prepare aminoantiene derivatives in which a tertiary H atom of the adamantane skeleton is substituted by an amino group and at least one to a maximum of all three further tertiary H atoms by a multiplicity of functional groups ,
  • Particularly preferred in this case are the preparation of 3-aminoadamantane-1-carboxylic acid derivatives in which the 5- or 7-position of the adamantane skeleton is arbitrarily substituted, as well as the linkage of the thus obtained monomeric amino acid derivatives to oligomers.
  • the present invention relates to the fields of chemistry, biochemistry, biology and pharmacology.
  • adamantane derivatives as endothelin, neurokinin or angiotensin antagonists or as anti-viral agents.
  • the antiviral properties of 3-aminoadamantane-1-carboxylic acid with respect to its effects against influenza are described in Neth. Appl. (1966), 8 pp. CODES: NAXXAN NL 6600715 19660721 CAN 66: 2279 AN: 1967: 2279.
  • DE 696 26 650 T2 describes the use of an aminoadamantane compound for the production of a medicament against agranulomatosis, wherein at least one of the four tertiary C atoms of the adamantane carries an amino group and the other three tertiary carbon atoms optionally by amino, alkyl or Aryl groups are substituted.
  • DE 691 30 408 T2 describes peptide derivatives as antagonists of the endothelin receptor in which the C-terminal amino acid in ⁇ -position carries a 1-alkyladamantyl group.
  • DE 690 02 950 T2 describes peptides having a non-cleavable transition state insert corresponding to the 10,11-position of a renin substrate (angiotensinogen), in which the insert may have a 1- or 2-adamantyl group as well as a secondary amino group in geminal position.
  • DE 44 06 884 A1 and DE 44 06 885 A1 describe amino acid derivatives for the therapy and prophylaxis of neurokinin-mediated diseases in which a natural or non-natural amino acid is C-terminal to the amino group of a 3-amino-4-dihydro 1 H-quinolin-2-one derivative and N-terminal via an amide bond to a ⁇ -adamantyl-1-yl-alkanecarboxylic acid is bound.
  • amino acid derivatives for the therapy and prophylaxis of neurokinin-mediated diseases are described in DE 195 41 283 A1, wherein the N-terminal amino acid can be linked to a 1-carboxy-3-acetamido-adamantyl group and the adamantyl group is furthermore optionally present in 5 - or 7-position may be OH-substituted.
  • DE 196 26 311 A1 describes 3-amino-2-hydroxybenzoic acid derivatives (for controlling pests on plants and industrial materials), the amino group of which is linked to a further carboxyl group and its carboxyl group with a further amino group in each case to the carboxylic acid amide, wherein it is the further amino group may be a 1-carboxy-3-amino-5,7-substituted adamantane derivative.
  • DE 2 318 461 describes 1 N-alkyl-substituted 3,5-dialkyl-1-aminoadamantane derivatives and their preparation.
  • Plasmodium malariae The effect of adamantane derivatives against protozoa of the genus Plasmodium is described, for example, in US Pat. No. 6,737,438 B2, US Pat. No. 6,825,230 B2, WO 2003/076425 A1, EP 0370320 B1 and US Pat. No. 6,486,199 B1. Plasmodia are the causative agents of malaria. The person skilled in the art is aware of four plasmodium species that cause malaria in humans: Plasmodium falciparum, Plasmodium ovale, Plasmodium vivax and Plasmodium malariae.
  • Plasmodium yoeli nigeriensis Plasmodium vinckei petteri
  • Plasmodium berghei Plasmodium berghei nigeriensis
  • Plasmodium berghei yoelii Plasmodium gallinaceum
  • Plasmodium gallinaceum II Plasmodium relictum.
  • the antiprotozoal action of adamantane derivatives against some of the non-human malaria-inducing plasmodia is also described in the patents cited above.
  • dibromoadamantane is obtainable by reaction of adamantane with bromine and iron filings in yields of 95 to 98%.
  • adamantane derivatives can also be halogenated one or more times by phase transfer catalysis, referred to below as PTC.
  • adamantane is dissolved in fluorobenzene and reacted with 10 to 50% strength aqueous NaOH, tetrabromomethane and catalytic amounts of tetra- (n-butyl) -ammonium bromide. It is known to the person skilled in the art that this PTC bromination-as well as PTC iodination-also regioselectively succeeds in adamantane derivatives, for example in the case of ethers, non-enolisable ketones, phenyl and phenoxy derivatives of adamantane.
  • the conversion of the haloadamantanes into alkyladamantanes is possible by reacting the haloadamantane derivatives with Grignard reagents and / or organolithium, as described in K. Takeuchi, T. Okazaki, T. Kitagawa, T. Ushino, K. Ueda, T. Endo, R. Notario: Influence of Alkyl Substitution on the Gas Phase Stability of 1-Adamantyl Cation and on the Solvent Effects in the Solvolysis of 1-Bromoadamantane. J. Org. Chem. 2001, 66 (6), 2034-2043 and G. Molle, J.E. Du- bois, P. Bauer, Can. J. Chem. 1987, 65, 2428.
  • the haloadamantane is treated with allyltrimethylsilane or its hetero analogs in the presence of Lewis acids, such as TiCl 4 or AICl 3 , and the resulting product is optionally subjected to a heterogeneously catalyzed hydrogenation.
  • Lewis acids such as TiCl 4 or AICl 3
  • R12, R13 are prop-2-enyl, 2-methyl-prop-1-enyl, cyclohex-1-enyl, N-acetyl-N-methylamino, (2-isothiazolidine 3-thionyl) methyl (or after the reaction 3- (4,5-dihydroisothiazolyl) sulfanyl, 3- (1H-benzoimidazolyl) methyl (or after the reaction 5- (1 H-benzoimidazolyl) methyl ), 2-hydroxyphenyl (or after the reaction A-hydroxyphenyl), 5- (1 H -imidazolyl) methyl, 3-but-1-enyl, 3- (2-methyl) prop-1-enyl, benzyl, 3 - (1H-indolyl) methyl, 4-hydroxyphenylmethyl; R13 may include, but are not limited to, propyl, 1,1-dimethylethyl (fer-butyl), cyclohexyl,
  • DE 23 18 461 describes a process for the preparation of 3,5-dialkyl-substituted 1-aminoadamantanes, in which 3,5-dialkyl-substituted 1-haloadamantane compounds with urea or an N 1 N ' Dialkylurea derivative is reacted at temperatures of 120 to 260 0 C and subsequently by cleavage of the resulting crude amide with concentrated mineral acids ßie the corresponding amine is released.
  • the 3,5-dialkyl-1-halo-adamantanes to be used as starting materials are preferably the chlorinated or brominated derivatives.
  • a disadvantage of this process is that halogenated adamantane compounds must be used and numerous reaction steps must be carried out. Due to the necessity of reacting haloadamantanes and urea derivatives with one another at high temperatures, this process is also very energy-consuming.
  • Cyclic peptides play an important role in the construction of artificial ion channels.
  • Artificial ion channels are known to the person skilled in the art and are described, for example, in N. Voyer, M. Robitaille: "A novel functional artificial ion channel", J. Am. Chem. SOG., 1995, 117, 6599-6600 and V. Sidorov, FW Kotch , JL Kuebler, YF Lam, JT Davis: “Chloride transport across lipid bilayers and transmembrane potential induction by an oligophenoxyacetamide", J. Am. Chem. Soc. 2003, 125, 2840-2841.
  • these artificial ion channels In order to be able to form a channel structure, these artificial ion channels must possess some key properties: they must span the lipid layer of the cell membrane and be amphiphilic, ie have both polar and hydrophobic sections. This amphiphilia directs the polar "head groups" towards the outer, aqueous environment of the membrane, while the hydrophobic region anchors itself in the cell membrane.
  • Many of the artificial ion channels known hitherto consist of comparatively simple and repeating molecular units artificial ion channel is the pore diameter of these molecules, since it influences the channel selectivity of the channel and permits the passage of ions, for example potassium, sodium, calcium or chloride ions, by means of size exclusion. Ideally, such an ion channel favors a particular ion, with the ion's active rate of transport through the channel being in the range of 10 4 to 10 8 ions per second.
  • helical molecules are used, with the ion channel being formed either within a helix or between interconnected helices. This concept is referred to as a protein-based or helical (ion) channel.
  • ion helical
  • compounds whose selectivity for certain alkali metal ions is known. These compounds are used as selective filters and combined with membrane-exciting molecules, the latter guiding the ions to and from the selective filters. This concept is called an ionophore-based ion channel. Both concepts are known to the person skilled in the art and can be found, for example, in PJ.
  • Peptidic catalysts and their use for pharmaceutical purposes are known to the person skilled in the art and are described, for example, in MM Vasbinder, ER Jarvo, SJ. Miller, Angew. Chem. Int. Ed. 2001, 40, 2824-2827 and F. Formaggio, A. Barazza, A. Bertocco, C. Toniolo, QB Broxterman, B. Kaptein, E. Brasola, P. Pengo, L. Pasquato, P. Scrimin, J. Org. Chem. 2004, 69, 3849-3856. However, so far mainly peptidic catalysts are known, which are based essentially on chain-shaped, oligomeric ⁇ -amino acids in the D and L configuration.
  • GABA ⁇ -aminobutyric acid
  • GABA transporters occur in all parts of the brain, for example in the hippocampus, in the hypothalamus, in the medulla and in the prefontal cortex, furthermore in the spinal cord and in most inhibitory synapses of the nervous system. This is known to the person skilled in the art and can be found, for example, in LA Borden, KE Smith, PR Hartig, TA Branchek, RA Weinshank, Molecular heterogeneity of the gamma-aminobutyric acid (GABA) transport system. J. Biol. Chem. 1992, 267, 21098-21104 nachgeschla ⁇ gene. Disorders of GABA metabolism lead to numerous diseases, including, for example, Parkinson's disease, Huntington's disease, Alzheimer's disease, autism, Tourette's syndrome, hypertension, sleep disorders, attention deficit hyperactivity disorder (ADHD).
  • ADHD attention deficit hyperactivity disorder
  • the novel 3-aminoadamantane-1-carboxylic acids are much more lipophilic by the cycloaliphatic adamantane core, which facilitates the crossing of the blood-brain barrier and with regard to the three-dimensional arrangement of the functional groups, in particular the carboxy or amino function, fixed.
  • a further object of the invention is to provide processes for the preparation of these substances and for the oligomerization of the monomeric 5,7-substituted 3-aminoadamantane-1-carboxylic acids obtainable in this way, the oligomers being linear or cyclic. This object is achieved by the claims 10 to 15.
  • the present invention overcomes the disadvantages of the prior art in that it provides a variety of 3, 3,5 and 3,5,7-substituted aminoadamantane compounds. Furthermore, the present invention provides methods to - produce 3- and 3,5-substituted Aminoadamantanharmen invention by direct acetamidation and
  • the monomeric and oligomeric 5,7-substituted 3-aminoadamantane-1-carboxylic acid derivatives according to the invention are suitable as antiviral agents, GABA analogues, persistent oligopeptides, artificial ion channel builders, and building blocks for peptidic catalysts.
  • the compounds of the invention substituted in the 3- and / or 5- and / or 7-position of the 1-aminoadamantane skeleton have the general structural formula
  • R1 and R2 are independently: H, F, Cl, Br, I;
  • R1 and R2 are each independently a fatty acid radical -CH 2 - (C r H 2r) -COOH, -CH 2 - (C r H 2r - 2) -COOH, -CH 2 -. (C r H 2l 4 ) COOH,
  • R 1 and R 2 independently of one another represent the radical R 6 of an amino acid
  • R6 is preferably benzyl, 4-hydroxybenzyl, - (1H-indolyl) -methyl, (1H-imidazolyl) -methyl, 4-amino-butyl-, (3-guanidyl) -propyl, (2-methylthio) ethyl, hydroxymethyl, (R) - (I -hydroxy) -ethyl, (S) - (I -hydroxy) -ethyl, (2-carboxy) -ethyl, (R) - (2-carbamoyl-1-methyl) -ethyl, (S) - (2-carbamoyl-1-methyl) -ethyl, carboxymethyl, thiomethyl, (2-carbamoyl) -ethyl, (carbamoyl) -methyl -, selenomethyl, (3-
  • A is not an atom
  • each unit AS is a natural or non-natural ⁇ -, ⁇ -, ⁇ - or ⁇ - amino acid in the D- or L-
  • R4 -H or L, wherein L has the meanings listed under R1, R2 and where L optionally carries one to three substituents selected from the group -F; Cl;
  • B is no atom or (AS) q , wherein each unit AS is a natural or non-natural ⁇ -, ß-, ⁇ - or ⁇ - amino acid in the D or L configuration, q a whole Number of O to 10 is the amino acids within the peptide chain q are identical or different, and wherein the C-terminus of (AS) q to that with the adamantyl linked nitrogen atom is attached as well as the N-terminus of (AS) q is bound to R5, or B is a 2- to 10-membered depsipeptide, wherein each amino acid within the depsipeptide is a natural or non-natural ⁇ -, ß-, ⁇ - or ⁇ - amino acid in the D- or L-configuration and wherein each carboxylic acid within the depsipeptide is an aliphatic, aromatic or araliphatic carboxylic acid having 1 to 10 Koh ⁇ lenstoffatomen, wherein aliphatic Groups are linear, cyclic or
  • n 1-40 and a natural number, if it is an open-chain compound, wherein R1, R2, R3, A and B in each unit n are identical or under Kunststoff ⁇ Lich and at least one of the groups R1, R2 and R4 is separated from hydrogen,
  • a and B are not an atom
  • a and B are not an atom
  • n 1
  • the radicals R1 and R2 are lower straight-chain or branched alkyl radicals
  • R3 is hydrogen, a lower, straight-chain, branched or cyclic alkyl radical and the radical R5 is hydrogen or the methyl group.
  • R14 and R15 are independent of each other:
  • L -alkyl, -cycloalkyl, -heterocycloalkyl, -aryl, -heteroaryl, -alkylaryl, -alkylheteroaryl, -alkylcycloalkyl, -alkylheterocycloalkyl, where -alkyl represents a group having 1 to 10 carbon atoms, preferably methyl, ethyl, propyl, Isopropyl, 1-butyl, 2-butyl, (2-methyl) propyl, tert -butyl; -Alkyl can be linear or branched, -cycloalkyl is a group having 3 to 20 carbon atoms, the heterocyclic groups are a radical having 1 to 20 carbon atoms, in which up to 5 carbon atoms are selected by heteroatoms selected from the group of nitrogen, oxygen, Sulfur, phosphorus are replaced, -aryl is an aromatic radical having 5 to 20 carbon atoms and hetero
  • R14 and R15 independently of one another are a fatty acid radical
  • R 16 is -alkyl, -cycloalkyl, -heterocycloalkyl, -aryl, -heteroaryl, -alkylaryl, -alkylheteroaryl, -alkylcycloalkyl, -alkylheterocycloalkyl, -alkyl being a group having 1 to 10 carbon atoms, preferably methyl, ethyl, Propyl, isopropyl, 1-butyl, 2-butyl, (2-methyl) propyl, tert-butyl, 1-adamantyl and -alkyl are linear or branched, -cycloalkyl and the heterocyclic groups are a radical with 1 to 20 carbon atoms, wherein up to 5 carbon atoms are replaced by heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus, -aryl is an aromatic radical having 5 to 20 carbon atoms and heteroaryl is a corresponding aromatic radical
  • alkyl alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylaryl,
  • -Alkyl are linear or branched, -cycloalkyl and the heterocyclic groups are a radical having 1 to 20 carbon atoms, wherein up to 5 Kohlenstoffato ⁇ me by heteroatoms selected from the group nitrogen, oxygen, sulfur, phosphorus are replaced, -Aryl for a heteroaryl is a corresponding aromatic radical in which up to 5 carbon atoms are replaced by heteroatoms selected from the group consisting of nitrogen, oxygen, sulfur, phosphorus, wherein L is optionally one to three substituents selected from the group -O- (C 1 -C 10 -alkyl); -S- (C 1 -C 10 -alkyl); -SO 3 H; -COOH; -NH 2, -NH (C r Ci 0 alkyl); -N (Ci-Ci O - alkyl) 2 , wherein the two alkyl groups are identical or different, and wherein alkyl groups are linear, cyclic or branched.
  • 1 equivalent corresponds to a multiple of 0.9 mol to 1, 1 mol and 1 volume of the same multiple of 0.2 L to 0.3 L.
  • a mixture of an alcohol R17-OH and diethyl ether in a volume ratio of 1: 1 to the reaction mixture if a product is prepared in which R17 is not hydrogen, wherein the volume of the alcohol / ether mixture is substantially the Volume of the reaction mixture corresponds.
  • the resulting solution is extracted 2 to 5 times with 4 parts by volume of diethyl ether, the combined organic phases are dried with anhydrous Na 2 SO 4 and filtered through 5-10 parts by volume of a basic metal oxide, preferably basic Al 2 O 3 .
  • the amide is obtained as a white solid in yields of 60-98%.
  • the alcohol R17-OH is preferably methanol, ethanol, n-propanol, n-butanol.
  • the ether which is used for the preparation of the alcohol-ether mixture is a dialkyl ether, preferably diethyl ether, diisopropyl ether or tert-butyl methyl ether.
  • the amide 12 can then be reacted by reaction with a concentrated mineral acid, for example HCl, to form the salt of the corresponding amine.
  • a concentrated mineral acid for example HCl
  • the hydrochloride of the amine is obtained.
  • mixed di-halo-adamantane derivatives 14 are selectively converted into monohalocarboxamides 15 implemented.
  • Mixed dihalides are understood to mean those 1,3-dihalo adamantane derivatives in which the two halogen atoms are different.
  • Selective means here that the more reactive of the two halogen atoms is converted into a carboxylic acid amide, wherein a reactivity of the halogens in the series I>Br>Cl> F applies.
  • Such a selective reaction of mixed dihalides is not known in the prior art.
  • the halocarboxylic acid amides 15 prepared by the process according to the invention can then optionally be treated with conc. Sulfuric acid and CO produced in situ after aqueous workup to Acetamidoadamantan- carboxylic acid derivatives 16 are reacted.
  • the cleavage of the acetamide is carried out by heating the carboxylic acid amides with conc. HCl for 15 to 72 h.
  • the novel 5- and / or 7-substituted 3-aminoadamantane-1-carboxylic acids 17 are obtained as hydrochlorides.
  • the mixed dihalides 14 are reacted according to the invention to Monohalogeno- carbonklamid.
  • SET-oxidant a one-electron oxidant
  • reaction mixture for 0.5 - h 3, preferably for 1 h, stirred, wherein they are to -15 to 0 0 C, vorzugt -10 0 C, warmed Subsequently, a mixture of water (or egg nem alcohol) and diethyl ether in a volume ratio.
  • the aqueous phase is mixed two to four times, preferably three times, with 0.2 part by volume of an ether extracted and the united ethereal n phases are then two to four times, preferably three times, with 0.2 parts by volume of saturated NaHSOß- solution, then one to three times, preferably twice, with 0.2 parts by volume of water and finally one to two times with 0.2 parts by volume of a saturated Washed saline.
  • the solvents are then removed by means of distillation under reduced pressure.
  • the SET oxidant is preferably NOBF 4 or NOSF ⁇ .
  • R1 and R2 are H, F, Cl, Br, I; or
  • R1 and R2 independently of one another are a fatty acid radical
  • R 1 and R 2 independently of one another represent the radical R 6 of an amino acid
  • R6 being preferably benzyl-, 4-hydroxybenzyl-, - (1H-indolyl) -methyl-, (1H-imidazolyl) -methyl-, 4-amino-butyl-, (3-guanidyl) -propyl, (2-
  • 1-adamantyl optionally containing one to three substituents selected from the group -F; -Cl; Br; -I; -OH; -O- (d-Cio-alkyl); SH; -S- (C 1 -C 10 -alkyl); -SO 3 H; - CN; -COOH; -COO- (C r C 10 alkyl); -CONH 2 ; -CONH (C r C 10 alkyl); -CON (C 1 -C 0 - alkyl) 2 wherein the two alkyl groups are identical or different; -NH 2 , - NH (Ci-C- ⁇ o-alkyl); -N (C 1 -C 10 -alkyl) 2, where the two alkyl groups are identical or different, and the alkyl groups have the meanings listed under R 1 and R 2.
  • R5-CN is preferably acetonitrile, chloroacetonitrile, trichloroacetonitrile, propionitrile, chloropropionitrile, n-butyronitrile or 3-carboxyadamantane-1-carbontril.
  • the alcohol R3-OH which is used for the preparation of the alcohol-ether mixture is preferably methanol, ethanol, n-propanol, n-butanol.
  • the ether which is used for the preparation of the water or alcohol-ether mixture is a dialkyl ether, preferably diethyl ether, diisopropyl ether or Fe / t-butyl methyl ether.
  • the preparation of amides from alkyl or arylalkyl halides and nitriles in the presence of SET oxidants is known in the art and described in GA Olah, BG Gupta, SC Narang: Synthesis-Stuttgart 1979, 274-276.
  • this process is also suitable for the direct and selective introduction of carboxylic acid amides in mixed 1,3-dihaloadamantane derivatives.
  • mixed dihalides react chemoselectively, ie. H. the reactive halogen initially reacts completely before the less reactive halogen is attacked, the reactivity in the series I> Br> Cl> F decreasing.
  • the choice of reaction conditions in the PTC and the introduction of the carboxylic acid amide is crucial.
  • haloamides obtained by means of the process according to the invention for the direct preparation of carboxylic acid amides from mixed 1,3-dihaloadamantane derivatives are converted into the corresponding carboxylic acid in a Koch-Haaf reaction with carbon monoxide produced in situ.
  • the Koch-Haaf reaction is well known to those skilled in the art and can be found in organic chemistry textbooks, for example J. March: Advanced Organic Chemistry, Third Edition, John Wiley & Sons, New York, 1985.
  • a solution of the haloacetamide in conc. Sulfuric acid (95-98%) prepared and mixed for 2 to 6 hours, preferably 3 hours, with carbon monoxide.
  • the addition of carbon monoxide can be carried out in a manner known to the person skilled in the art either by introducing it as CO gas or by producing the CO in situ by dropwise addition of formic acid. Subsequently, the reaction mixture is poured onto ice, the crude product is filtered off and recrystallized. Suitable solvents for the recrystallization are methanol, acetic acid, formic acid, acetone, water and mixtures thereof. The cleavage of the amides is known to the person skilled in the art and is carried out, for example, by heating in a concentrated mineral acid.
  • Alternative method for the production of 5 resp. 5,7-substituted-3-aminoadamantane-1-carboxylic acids are known to the person skilled in the art.
  • a protective group referred to in the scheme as "PG" is first introduced into the amino function of the inventive 3-aminoadamantane-1-carboxylic acids 18 according to known protocols (TW Greene, PGM Wuts, "Protective groups in organic synthesis ", 2 nd Edition, 1991, John Wiley & Sons Inc., New York / Chichester / Brisbane / Toronto / Singapore).
  • This protecting group is selected from the group acetal, acyl, silyl, benzyl protecting groups, tert-butyloxycarbonyl (Boc), benzyloxycarbonyl (Cbz), benzyl ether (Bn) and fluorenyl 9-methoxycarbonyl (Fmoc), preferably Boc.
  • the 3-amidoadamantane-1-carboxylic acids 16 are used. It is known to the person skilled in the art that the amido function as such already represents a protective group PG from which, as described above, the corresponding amines are present by cleavage with mineral acids and can optionally be converted into further amino derivatives.
  • the carboxyl function of the 3-acylamidoadamantane-1-carboxylic acids according to the invention 16 or 3-aminoadamantane-1-carboxylic acids 18 are preferably protected by esterification, by firstly using thionyl or oxalyl chloride to represent the corresponding carboxylic acid chloride and then closing it with an alcohol R18-OH is reacted.
  • R 18 is alkyl, wherein alkyl contains 1 to 10 C atoms and is linear or branched, and / or cycloalkyl having 3 to 10 C atoms and / or 1-adamantyl.
  • the substances 22 protected in this way at the carboxyl and the amino group are again subjected to a phase-transfer catalytic halogenation.
  • the C-terminus of the peptidic acid is activated with an activating reagent, wherein the activating reagent is selected from the group DIC, DCC, EDC, FmocOPfp, PyClop, HBTU, HATU, HOSu, TBTU, T3P, BopCl and 3-CI-1-pyridinium iodide.
  • Suitable coupling additives are the substances HOBt, HOAt and HONB known to the person skilled in the art. It is known to those skilled in the art that these reactions are conveniently carried out with the addition of a base such as, for example, Dl-PEA. The person skilled in the art will continue to be aware of various solvents for use in said processes.
  • the linear peptide contains, in addition to the C-terminal free COOH group, further free COOH groups within the peptide chain, such as, for example, COOH groups of glutamic acid and / or aspartic acid, these must not have C-terminal free COOH groups before the reaction of the linear Peptides are protected with an activating reagent with a suitable orthogonal protecting group, which must be cleaved again after preparation of the substrate according to the invention.
  • Suitable protecting groups and appropriate methods for their removal are known in the art and can, for example nd Editi ⁇ on 1991 in TW Greene and PGM Wuts, "Protective groups in organic synthesis", 2, John Wiley & Sons Inc., New York / Chichester / Brisbane / Toronto / Singapore.
  • the Induced-Fit theory is an extension of the key-lock principle, according to which a substrate (key) binds to a specific binding site in the enzyme (lock) by weak, non-covalent interaction in order to determine the transition state (English).
  • the conformation of the enzyme changes as a result of binding of the substrate, which makes the specific enzyme-substrate interaction possible in the first place
  • they can be read in JM Berg, JL Tymoczko, L Stryer: “Biochemie”, Spektrum-Verlag, Heidelberg, 4th ed., 1996.
  • their lipophilicity which is substantially increased over ⁇ -peptides, by the bulky aliphatic adamantane building block;
  • the 3-aminoadamantane-1-carboxylic acid derivatives according to the invention are suitable both as protein channels and as ionophore-based ion channels, since they have the following key properties: (a) amphiphilia;
  • one or more strands of an oligopeptide forms a helix or double helix, which form the ion channel after being incorporated into the cell membrane, if the peptides according to the invention are linear and 4 to 40, preferably 16 to 18, units of n shown on page 16 Contain adamantane derivatives.
  • the helical or ionophore structure and the amphiphilic properties of the oligopeptides according to the invention can be individually adjusted by varying R1 and / or R2.
  • the monomeric or oligomeric 5,7-substituted 3-aminoadamantane-1-carboxylic acid derivatives prepared by the process according to the invention can furthermore be used as medicaments for patients for the therapy, diagnosis and prophylaxis of diseases in which viral infections occur.
  • the antiviral activity of unsubstituted and 3,5-substituted aminoantiamane derivatives is known;
  • the present invention provides a broad spectrum of further aminoadamantane derivatives for the treatment of viral infections in humans and animals.
  • some viruses - for example, the hepatitis C virus (HCV) and the BVD virus (bovine viral diarrhea virus) form even ion channels and thus impair functions of their host cells.
  • the Monomeric or oligomeric 5,7-substituted-3-aminoadamantane-1-carboxylic acid derivatives according to the invention can act both as antivirals and as artificial ion channels and thus prevent the functionality of viruses.
  • the monomeric or oligomeric 5,7-substituted 3-aminoadamantane-1-carboxylic acid derivatives prepared by the process according to the invention can furthermore be used as medicaments for patients for the therapy, diagnosis and prophylaxis of diseases in which infections by protozoa of the genus Plasmodium occur , Plasmodia are the causative agents of malaria.
  • Plasmodium falciparum Plasmodium ovale
  • Plasmodium vivax Plasmodium malariae.
  • Further plasma species known to the person skilled in the art are, for example, Plasmodium yoeli nigeriensis, Plasmodium vinckei petteri, Plasmodium berghei, Plasmodium berghei nigeriensis, Plasmodium berghei yoelii, Plasmodium gallinaceum, Plasmodium gallinaceum II and Plasmodium relictum.
  • the antiprotozoic activity of adamantane derivatives is known;
  • the present invention provides a broad spectrum of further adamantane derivatives for the preparation of medicaments for the diagnosis, prophylaxis and therapy of plasmodium infections in humans and animals, in particular for the production of medicaments against malarial infections in humans.
  • the monomeric or oligomeric 5,7-substituted 3-aminoadamantane-1-carboxylic acids according to the invention are ⁇ -amino acids in the classical sense and are therefore furthermore suitable as building blocks in peptidic catalysts. This suitability is based on the following properties:
  • GABA ⁇ -aminobutyric acid
  • the enhanced GABA lipophilicity of the 5,7-substituted 3-aminoadamantane-1-carboxylic acids according to the invention makes it easier to cross the blood-brain barrier; the fixed arrangement of the functional groups zuein ⁇ other and the range of variation in R1 and R2 allow targeted influencing / blocking of different receptor and pump systems. Furthermore, the 5,7-substituted 3-aminoadamantane-1-carboxylic acids according to the invention exhibit increased protease stability and are therefore more stable in vivo than other ⁇ -amino acids which do not have the conformationally rigid adamantane skeleton.
  • the 5,7-substituted-3-aminoadamantane-1-carboxylic acids according to the invention can be used for patients for the therapy, diagnosis and prophylaxis of diseases in which a dysfunction of the GABA system occurs, such as Parkinson's disease, Huntington's disease, Alzheimer's disease, autism, Tourette syndrome, hypertension, sleep disorders, attention deficit hyperactivity disorder (ADHD), psychoses, panic and anxiety disorders, posttraumatic stress syndrome, bipolar disorder. mood disorders such as manic-depressive disorders, schizophrenia.
  • diseases in which a dysfunction of the GABA system occurs such as Parkinson's disease, Huntington's disease, Alzheimer's disease, autism, Tourette syndrome, hypertension, sleep disorders, attention deficit hyperactivity disorder (ADHD), psychoses, panic and anxiety disorders, posttraumatic stress syndrome, bipolar disorder.
  • ADHD attention deficit hyperactivity disorder
  • psychoses panic and anxiety disorders
  • posttraumatic stress syndrome bipolar disorder.
  • mood disorders such as manic-depressive disorders, schizophrenia.
  • the term "patient” refers equally to humans and vertebrates.
  • the drugs can be used in human and veterinary medicine.
  • Pharmaceutically acceptable compositions of compounds according to the claims may be used as mono- to oligomers or as their salts, esters, Amide or "prodrugs” are present, provided they do not trigger excessive toxicity, irritations or allergic reactions on the patient according to a reliable medical assessment.
  • Prodrug is understood to mean an active ingredient which is administered as a precursor and enzymatically transformed into an active substance in the organism. is being mingled.
  • the therapeutically active compounds of the present invention may be administered to the patient as part of a pharmaceutically acceptable composition either orally, rectally, parenterally, intravenously, intramuscularly, subcutaneously, intracentrally, intravaginally, intraperitoneally, intravascularly, intrathecally, intravesically, topically, locally (powder, ointment or drops) or in spray form (aerosol).
  • a pharmaceutically acceptable composition either orally, rectally, parenterally, intravenously, intramuscularly, subcutaneously, intracentrally, intravaginally, intraperitoneally, intravascularly, intrathecally, intravesically, topically, locally (powder, ointment or drops) or in spray form (aerosol).
  • the intravenous, subcutaneous, intraperitoneal or intrathecal administration can be carried out continuously by means of a pump or dosing unit.
  • Dosage forms for topical administration of the compounds of the invention include ointments, powders, s
  • Exemplary embodiment 1 is a diagrammatic representation of Exemplary embodiment 1:
  • reaction mixture is poured onto 600 g of ice. It is then extracted with diethyl ether (4 ⁇ 50 ml), the combined organic phases are dried with Na 2 SO 4 and the ether is removed on a rotary evaporator.
  • the crude product is with
  • Embodiment 3 1-Bromo-3-iodo-5,7-dimethyladamantane
  • the reaction begins, as indicated by a brown coloration and gas evolution.
  • the evolution of gas is completed. It is mixed with 20 mL of water and 30 mL of diethyl ether, then the phases are separated and the aqueous phase extracted with diethyl ether (3 times 25 mL). The combined ethereal phases are washed with NaHSO 3 solution, water and sat. Saline (2 x 20 mL each) and dried with Na 2 SO 4 . After filtering off the desiccant and removing the solvent on the rotary evaporator i. Vak.
  • This substance is prepared according to a modified protocol by Stepanov et al. (FN Stepanov, Yl Srebrodolskii, J. Org. Chem. USSR 1966, 2, 1612-1615).
  • Stepanov et al. FN Stepanov, Yl Srebrodolskii, J. Org. Chem. USSR 1966, 2, 1612-1615.
  • 6.5 g (24.5 mmol) of the acetamide are mixed with 155 ml of conc. HCl 3 d heated to reflux. After cooling, the reaction mixture is concentrated on a rotary evaporator at 100-400 mbar and 90 0 C to dryness. The remaining residue is digested with 40 ml of ice-cold acetone, filtered off with suction and washed with 20 ml of ice-cold acetone.
  • Embodiment 7 is a diagrammatic representation of Embodiment 7:
  • Embodiment 9 is a diagrammatic representation of Embodiment 9:
  • the solution is warmed to RT over 4 h and stirred at RT for 7 d.
  • the THF is then removed on a rotary evaporator at 15 mbar and 70 0 C to dryness, then taken up with 60 mL of diethyl ether and extracted 25 times with 30 mL of water. Thereafter, the diethyl ether is removed at 15 mbar and 60 0 C on a rotary evaporator to dryness.
  • IR (KBr compact): 3357.5, 3065.7, 2909.2, 2855.7, 1718.3, 1649.4, 1512.9, 1450.9, 1366.7, 1252.2, 1167.4, 1081.4, 740.2cm "1 .
  • Embodiment 10 is a diagrammatic representation of Embodiment 10:
  • the t / t-butyl ester thus prepared is chromatographed on an HPLC column from the company Macherey-Nagel (Nucleodex® ⁇ -PM, 4 mm ⁇ 150 mm, particle size 5 ⁇ m, eluent: methanol / water (70:30)) the enantiomers separated.
  • Embodiment 11 is a diagrammatic representation of Embodiment 11:
  • mice Female African clawed frogs (Xenopus laevis) are anesthetized with Tricaine (MS222, Sandoz, Basel / Switzerland, 1 g L "1 ), parts of the ovary are removed and treated with collagenase to remove follicular cells the experiments are selected adult oocytes.
  • Tricaine MS222, Sandoz, Basel / Switzerland, 1 g L "1
  • cRNA of the GABA transporter GAT1 from mouse brain is injected (about 50 ng per oocyte).
  • oocytes and untreated control-oocytes is injected into the no cRNA are (at 19 0 C in oocyte Ringer solution ORi composition in mM: NaCl 90, KCl 2, MgCl 2 2, MOPS (morpholinopropanesulfonic acid) / Tris 5 (adjusted to pH 7.4), gentamicin (70 mg L "1 )) for 3 days.
  • the uptake of the substances is determined by incubating in each case 10 of the oocytes pretreated as described above in about 200 ⁇ l of ORi solution at room temperature (21 ° C.) for 20 minutes
  • the ORi used here contains 400 ⁇ M GABA, from which about 1 uM H-3 labeled are and 1 mM of the substances 46 - 53.
  • the oocytes are gewa ⁇ rule and SDS solution (10th % aqueous SDS in double-distilled water.) lysed.
  • the ge dissolved oocytes are treated with 3 ml of scintillation solution (Rotiszint Eco Plus), incubated for 2 h at 40 0 C, shaken, and the radioactivity is determined using a scintillation counter.
  • Rotiszint Eco Plus 3 ml of scintillation solution
  • Embodiment 12 is a diagrammatic representation of Embodiment 12
  • Fig. 1 X-ray structure analysis of 3- (9-fluorenylmethoxycarbonylamido) -tricyclo [3.3.1.1 3> 7 ] decane-1-carboxylic acid (36) ORTEP preparation of 3- (9-fluorenylmethoxycarbonylamido) tricyclo [3.3.1.13,7 ] decane-1-carboxylic acid, thermal ellipsoids with 50% probability of residence.
  • Fig. 2 Inclusion of ⁇ -aminoadamantane carboxylic acid derivatives by the
  • the concentration of the investigated substances is in each case 1000 ⁇ M.
  • Fig. 3 Concentration dependence of blocking of mGAT1 by

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des dérivés de 1-aminoadamantane et des dérivés d'acide 3-aminoadamantane-1-carboxylique, dans lesquels la position 5 ou 7 du squelette adamantane peut être substituée de manière quelconque. L'invention concerne également des procédés pour produire ces composés ainsi que des procédés pour lier les dérivés d'acide 3-aminoadamantane-1-carboxylique monomères ainsi obtenus pour former des oligomères. Les composés selon l'invention sont appropriés comme principes actifs antiviraux, canaux ioniques artificiels, ainsi que pour la thérapie, le diagnostic et la prophylaxie de maladies dans lesquelles apparaît un dysfonctionnement du système GABA.
EP05771230A 2004-07-23 2005-07-22 Derives d'aminoadamantane, leurs procedes de production et leur utilisation Withdrawn EP1789380A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004035978A DE102004035978A1 (de) 2004-07-23 2004-07-23 Aminoadamantan-Verbindungen
DE102005032380 2005-07-08
PCT/DE2005/001304 WO2006010362A1 (fr) 2004-07-23 2005-07-22 Derives d'aminoadamantane, leurs procedes de production et leur utilisation

Publications (1)

Publication Number Publication Date
EP1789380A1 true EP1789380A1 (fr) 2007-05-30

Family

ID=35169540

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05771230A Withdrawn EP1789380A1 (fr) 2004-07-23 2005-07-22 Derives d'aminoadamantane, leurs procedes de production et leur utilisation

Country Status (3)

Country Link
US (1) US20080275112A1 (fr)
EP (1) EP1789380A1 (fr)
WO (1) WO2006010362A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20050833A1 (it) * 2005-05-10 2006-11-11 A M S A S P A Anonima Materie Sintetiche Affini Nuovo procedimento per la sintesi di aminoadamantani
DE102006009278B4 (de) * 2006-03-01 2010-06-02 Justus-Liebig-Universität Giessen Verfahren zur direkten Formamidierung oder Acetamidierung von Admantan und Admantanderivaten sowie deren Verwendung zur Herstellung von Aminoadmantanen
DE102006009279A1 (de) 2006-03-01 2007-09-06 Justus-Liebig-Universität Giessen Verfahren zur Herstellung von 1-Formamido-3,5-dimethyladamantan
RU2348611C1 (ru) * 2007-05-02 2009-03-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения n,n-диалкилзамещенных амидов адамантилалкилкарбоновых кислот
RU2344122C1 (ru) * 2007-07-09 2009-01-20 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения диалкиламидов 3-бром-1-адамантилалканкарбоновых кислот
WO2009057140A2 (fr) * 2007-10-30 2009-05-07 Msn Laboratories Limited Procédé amélioré pour le chlorhydrate de mémantine
EP2274276B1 (fr) * 2008-03-20 2014-07-09 Merz Pharma GmbH & Co. KGaA Procédé de préparation de mémantine et d un produit intermédiaire
EP2103597A1 (fr) * 2008-03-20 2009-09-23 Merz Pharma GmbH & Co.KGaA Procédé pour la fabrication de mémantine et d'un produit intermédiaire
DE102008027341A1 (de) 2008-06-07 2009-12-10 Justus-Liebig-Universität Giessen Monoveretherte Diole der Diamantoiden
WO2011015265A2 (fr) * 2009-08-04 2011-02-10 Merck Patent Gmbh Dispositifs électroniques comprenant des hydrocarbures polycycliques
EP2399926A1 (fr) 2010-06-22 2011-12-28 Justus-Liebig-Universität Giessen Peptides comportant 3-aminoadamantane acides carboxyliques améliorent la plasticité synaptique et agissent comme agents neurogène
CN107365255A (zh) * 2016-05-11 2017-11-21 常州制药厂有限公司 一种工业化的盐酸美金刚生产方法
CN110938006A (zh) * 2019-12-04 2020-03-31 重庆植恩药业有限公司 盐酸美金刚杂质c的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1074331A (en) * 1964-09-28 1967-07-05 Leo Pharm Prod Ltd Penicillins
US3450744A (en) * 1967-04-25 1969-06-17 Sun Oil Co Dicarbamate derivatives of alkyladamantanes
US3564046A (en) * 1969-05-16 1971-02-16 Amchem Prod Quaternary ammonium derivatives of limonene
US3730956A (en) * 1971-11-26 1973-05-01 Lilly Co Eli 4 adamantylamino quinolines
GB1513135A (en) * 1974-06-04 1978-06-07 Res Inst For Med & Chem Inc Fluorination process and fluoro steroids
US4273704A (en) * 1979-12-03 1981-06-16 G. D. Searle & Co. N-Adamantane-substituted tetrapeptide amides
SK2582002A3 (en) * 1999-08-31 2003-02-04 Neurogen Corp Fused pyrrolecarboxamides as GABA brain receptor ligands
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US6486199B1 (en) * 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
US6737438B2 (en) * 2002-03-28 2004-05-18 Council Of Scientific And Industrial Research Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof
US6825230B2 (en) * 2002-06-21 2004-11-30 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trixolane antimalarials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006010362A1 *

Also Published As

Publication number Publication date
US20080275112A1 (en) 2008-11-06
WO2006010362A1 (fr) 2006-02-02

Similar Documents

Publication Publication Date Title
WO2006010362A1 (fr) Derives d'aminoadamantane, leurs procedes de production et leur utilisation
DE69627035T2 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
DE2947140C2 (fr)
SK283295B6 (sk) Substituovaná cyklická aminokyselina, jej použitie a farmaceutický prostriedok na jej báze
EP2252578A1 (fr) Nouveaux conjugues pour le traitement de maladies et troubles neurodegeneratifs
DE69714475T2 (de) Neue (alpha-aminophosphino) peptide, verfahren zu ihrer herstellung und ihre therapeutische verwendung
DE3177306T2 (de) Verfahren und Verbindungen zur Herstellung von H-ARG-X-Z-Y-TYR-R.
DE69013742T2 (de) Peptide und diese Peptide enthaltende Wirkstoffe gegen Dementia.
DE69722618T2 (de) Peptide
DE69506540T2 (de) Aminosulfonsäurederivate, ihre verwendung zur herstellung von pseudopeptiden und verfahren zu ihrer herstellung
DE69402935T2 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
DE69721052T2 (de) Alpha-aminosäureamide, ihre herstellung und ihre therapeutische anwendung
JPS58500811A (ja) 抗痙攣薬
DE60309847T2 (de) Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
CH630892A5 (en) Process for preparing bestatin compounds.
DE102004035978A1 (de) Aminoadamantan-Verbindungen
EP1043332B1 (fr) Dipeptides contenant d'acid aminés beta cyclopentane
DE69903974T2 (de) Anthraquinone antikrebs-arzneimitteln
EP0491263B1 (fr) Composés phénylalkylaminoalkyliques, procédé pour leur préparation et compositions pharmaceutiques qui les contiennent
AU2006217544B2 (en) Compounds for reducing aggregation of amyloid beta-peptide
DE69404624T2 (de) 15-Deoxyspergualine-Analoge, Verfahren in ihrer Herstellung und ihre Verwendung als Immunosuppressiva
EP0758342B1 (fr) Nouveau principe actif peptidique et sa production
WO2001096282A1 (fr) Procede de production d'amides ou d'esters
CA3191072A1 (fr) Composes carbamate de phenyle alkyle destines a etre utilises dans la prevention ou le traitement d'une maladie neurodegenerative
EP0804466A1 (fr) Nouveaux tetrapeptides, leur production et leur utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20081203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100827